Clinical and neurological peculiarities and pathogenetic mechanisms of tau protein involvement in the axonal brain damage and neurodegeneration
Keywords:tau protein, neurodegeneration, axonal brain damage
This investigation was carried out to study the content of microtubule-associated tau protein in sera of 42 patients with different neurodegenerative disorders (mean age of patients was 58.31 ± 13.49 years), among them there were eight patients with Alzheimer’s disease (mean age 69.76 ± 9.50 years), primary-generalized pharmacoresistant epilepsy (n = 23, mean age 40.95 ± 7.3 years) and Parkinson’s disease, tremor form (n = 11, mean age 51.38 ± 12.61 years), healthy controls (n = 30, mean age 42.11 ± 5.67 years). In this work for tau protein evaluation, immunofluorescence method was used with the primary and secondary monoclonal antibodies (SIGMA, USA). It was shown that tau protein content is evenly increased in almost all patients with neurodegenerative pathology, regardless of its course, with a tendency to higher values in patients with Alzheimer’s disease. Identification of tau protein may serve as a non-specific marker of axonal damage that accompanies various types of neurodegeneration.
Болезни нервной системы: В 2 т. / Под ред. Н.Н. Яхно, Д.Р. Штульмана. — М.: Медицина, 2001. — 480 с.
Ворлоу Ч.П., Деннис М.С., Гейн Ж.В. Инсульт. Практическое руководство для ведения больных: Пер. с англ. — СПб.: СП «Политехника», 1998. — 629 с.
Зенков Л.Р. Клиническая эпилептология (с элементами нейрофизиологии). — М.: Медицинское информационное агентство, 2002. — 416 с.
Иванов Ю.И., Погорелюк О.Н. Обработка результатов медико-биологических исследований на микрокалькуляторах. — М.: Медицина, 1990. — 218 с.
Avila J., Lucas J., Perez M., Hernandez P. Role of Tau Protein in both physiological and pathological conditions // Physiol. Rev. — 2004. — Vol. 84. — P. 361-384.
Bartosik-Psuiek H., Stelmasiak Z. The CSF levels of total-tau and phosphor-tau in patients with relapsing-remitting multiple sclerosis // J. Neural. Transm. — 2006. — 113. — P. 339-345.
Blennow K., Zetterberg H. // Alzheimer Disease Lancet. — 2006. — 368. — P. 387-403.
Bulut M., Koksal O., Dogan S. et al. Tau protein as a serum marker of brain damage in mild traumatic brain injury: Preliminary results // Advances in Therapy. — 2006. — № 23(1). — Р. 12-22.
Delacourte A. Tauopathies: recent insights into old diseases // Folia Neuropathol. — 2005. — № 43. — Р. 244-257.
Kapaki E., Paraskevaz G., Michalopoulou M., Kilidireas K. Increased cerebrospinal luid tau protein in multiple sclerosis // Eur. Neurol. — 2000. — № 43(4). — P. 228-232.
Lekomtseva Y., Gorbach T., Gubina-Vakulik G. High serum tau protein in patients with therapy-resistant intractable epilepsy under a baseline // J. of Neurology. — 2009. — Vol. 256(Suppl. 2). — P. S77.
Roder H.M., Hutton M.L. Microtubule-associated protein tau as a therapeutic target in neurodegenerative disease // Expert Opin. Ther. Targets. — 2007. — № 11(4). — Р. 435-442.
Terzi M., Birinci A., Cetinkaya E., Onar M.K. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis // Acta Neurol. Scand. — 2007. — 115(5). — Р. 325-30.
Uchihara T., Duyckaerts C., Seilhean D. et al. Exclusive induction of tau2 epitope in microglia/macrophages in inflammatory lesions-tautwopathy distinct from degenerative tauopathies // Acta Neuropathol. — 2005. — 109. — P. 159-164.
Zemlan P.F. US Patent 6589746. Method of detecting axonally-derived protein tau in patients with traumatic CNS injury // Traumatic CNS injury. — 2003.
Copyright (c) 2019 INTERNATIONAL NEUROLOGICAL JOURNAL
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.